Tissue engineering. Part A
-
The aim of this study is to investigate the efficacy and the effect of the dosage of the slow-released Escherichia coli-derived recombinant human bone morphogenetic protein 2 (ErhBMP-2) functionalized β-tricalcium phosphate (β-TCP) in repairing critical-sized bone defects. The functionalization was implemented by modifying the surface of β-TCP with biomimetic calcium phosphate coating with or without ErhBMP-2. Critical-sized calvarial defects were created in rats and filled with ErhBMP-2 functionalized β-TCP loaded with gradient doses of ErhBMP-2 (0, 50, 100, 150, 200, and 300 μg/g). ⋯ To develop a commercial product with more effective cost, Escherichia coli-derived rhBMP-2 (ErhBMP-2) has been produced and evaluated as an alternative to the mammalian-derived rhBMP-2. In this study, we prepared gradient ErhBMP-2 functionalized β-tricalcium phosphate (β-TCP) with biomimetic calcium phosphate coating and investigate their efficacy and dose effects. We revealed the dose effects of the slow-released ErhBMP-2 and demonstrated that ErhBMP-2 functionalized β-TCP could be a promising bone substitute for bone regeneration in clinical settings.